EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL

Gregory W Roloff, Ibrahim Aldoss iD, Noam E Kopmar iD, Chenyu Lin iD, Simone E Dekker, Vishal K Gupta iD, Timothy E O'Connor, Nikeshan Jeyakumar, Ibrahim N Muhsen iD, Yannis Valtis iD, Naveed Ahmed, Amy Zhang und 37 weitere

Journal of Clinical Oncology · 2025

DOI: 10.1200/jco.24.00321 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Gregory W Roloff und 48 weiteren Autor:innen. Beteiligte Einrichtung: Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE On the basis of the results of the ZUMA-3 trial, brexucabtagene autoleucel (brexu-cel), a CD19-directed chimeric antigen receptor T-cell therapy, gained US Food and Drug Administration approval in October 2021 for adults with relapsed/refractory (R/R) B-cell ALL (B-ALL). We report outcomes of patients treated with brexu-cel as a standard therapy. METHODS We developed a collaboration across 31 US centers to study adults with B-ALL who received brexu-cel outside the context of a clinical trial. Data were collected retrospectively from October 2021 to October 2023. Toxicities were graded per American Society for Transplantation and Cellular Therapy guidelines for cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). RESULTS At the time of data lock, 204 patients had undergone apheresis and 189 were infused. Median follow-up time was 11.4 months. Forty-two percent of patients received brexu-cel in morphologic remission and would have been ineligible for participation in ZUMA-3. After brexu-cel, 151 achieved complete remission (CR), of which 79% were measurable residual disease (MRD) negative remissions. Median progression-free survival (PFS) was 9.5 months and median overall survival was not reached. Grade 3-4 CRS or ICANS occurred in 11% and 31%, respectively. In multivariable analysis, patients receiving consolidative hematopoietic cell transplantation (HCT; hazard ratio, 0.34 [95% CI, 0.14 to 0.85]) after brexu-cel had superior PFS compared with those who did not receive any consolidation or maintenance therapy. CONCLUSION Similar to ZUMA-3, high rates of MRD-negative CR were observed after brexu-cel treatment for R/R B-ALL. The use of HCT as consolidation after brexu-cel resulted in improved PFS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptivePrecursor B-Cell Lymphoblastic Leukemia-LymphomaNeoplasm Recurrence, LocalHumansMaleAdultMiddle AgedFemaleRetrospective StudiesAgedAntigens, CD19Young AdultCytokine Release SyndromeReceptors, Chimeric AntigenAdolescentTreatment Outcome

Substanzen

Antigens, CD19Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL.
  • Division of Leukemia, Department of Hematology and Hematopoitic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
  • Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA.
  • Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC.
  • Division of Hematology-Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
  • Division of Hematology & Oncology, University of California Los Angeles, Los Angeles, CA.

ORCID-Profile: Ibrahim Aldoss, Noam E Kopmar, Chenyu Lin, Vishal K Gupta, Ibrahim N Muhsen, Yannis Valtis, Katharine Miller, Evan C Chen, Santiago Mercadal, Sean I Tracy, Bhagirathbhai Dholaria, Minoo Battiwalla, Aaron C Logan, Abdullah Ladha, Talal Hilal, Matthew P Connor, LaQuisa C Hill, Joshua P Sasine, Melhem M Solh, Vamsi K Kota, Noelle V Frey, Jae H Park, Marlise R Luskin, Wendy Stock, Ryan D Cassaday, Lori Muffly

Förderung

  • NCI NIH HHS

Zitieren

APA

Roloff, G. W., Aldoss, I., Kopmar, N. E., Lin, C., Dekker, S. E., Gupta, V. K., O'Connor, T. E., Jeyakumar, N., Muhsen, I. N., Valtis, Y., Ahmed, N., Zhang, A., Miller, K., Dykes, K. C., Ahmed, M., Chen, E. C., Mercadal, S., Schwartz, M., Tracy, S. I., …, & ROCCA Consortium (2025). Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL. Journal of Clinical Oncology. https://doi.org/10.1200/jco.24.00321

Vancouver

Roloff GW, Aldoss I, Kopmar NE, Lin C, Dekker SE, Gupta VK, et al. Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL. Journal of Clinical Oncology. 2025. doi:10.1200/jco.24.00321

BibTeX
@article{Roloff2025,
  author = {Roloff, Gregory W and Aldoss, Ibrahim and Kopmar, Noam E and Lin, Chenyu and Dekker, Simone E and Gupta, Vishal K and O'Connor, Timothy E and Jeyakumar, Nikeshan and Muhsen, Ibrahim N and Valtis, Yannis and Ahmed, Naveed and Zhang, Amy and Miller, Katharine and Dykes, Kaitlyn C and Ahmed, Mohamed and Chen, Evan C and Mercadal, Santiago and Schwartz, Marc and Tracy, Sean I and Dholaria, Bhagirathbhai and Mukherjee, Akash and Battiwalla, Minoo and Logan, Aaron C and Ladha, Abdullah and Guzowski, Caitlin and Hoeg, Rasmus T and Hilal, Talal and Moore, Jozal and Connor, Matthew P and Hill, LaQuisa C and Tsai, Stephanie B and Sasine, Joshua P and Solh, Melhem M and Kota, Vamsi K and Koura, Divya and Veeraputhiran, Muthu and Leonard, Jessica T and Frey, Noelle V and Park, Jae H and Luskin, Marlise R and Bachanova, Veronika and Galal, Ahmed and Pullarkat, Vinod and Stock, Wendy and Cassaday, Ryan D and Shah, Bijal D and Faramand, Rawan and Muffly, Lori and ROCCA Consortium, ROCCA Consortium},
  title = {Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1200/jco.24.00321}
}
Kostenlos starten →